SBI Securities
MAZE icon

SBI Securities’s Maze Therapeutics MAZE Stock Holding History

SBI Securities’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-6
Closed -$179 – 4229
2026
Q2 		$179 Hold
6
– – ﹤0.01% 3355
2026
Q1 		$179 Sell
6
-61
-91% -$2.69K ﹤0.01% 3261
2025
Q4 		$2.78K Buy
67
+6
+10% +$206 ﹤0.01% 2267
2025
Q3 		$1.58K Sell
61
-444
-88% -$7.5K ﹤0.01% 2516
2025
Q2 		$6.2K Buy
505
+479
+1,842% +$4.98K ﹤0.01% 1888
2025
Q1 		$286 Buy
+26
New +$313 ﹤0.01% 3087

Other funds holding MAZE

Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

SBI Securities's MAZE Position: Q3 2026 in Review

SBI Securities sold out of Maze Therapeutics (MAZE) in Q3 2026, closing a stake of 6 shares — an estimated $179 sold.

SBI Securities first reported a position in MAZE in Q1 2025 and held it in 6 quarters. The position peaked at $6.2K in Q2 2025. 9 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.

  • SBI Securities reported no remaining Maze Therapeutics position as of Q3 2026 after selling out during the quarter.
  • SBI Securities sold 6 Maze Therapeutics shares in Q3 2026, an estimated $179.
  • SBI Securities first reported a position in Maze Therapeutics in Q1 2025 and held it in 6 quarters.
  • SBI Securities's Maze Therapeutics position peaked at $6.2K in Q2 2025.
  • 9 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.